GENELUX Corp
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
GNLX$1.95-5.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · Treasury Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Total | |
| Balance at December 31, 2024 | 34,728,140 | $35 | (433,333) | $(433) | $278,001 | $64 | $(251,393) | $26,274 |
| Stock compensation | - | - | - | - | 1,423 | - | - | 1,423 |
| Unrealized loss on investments | - | - | - | - | - | (35) | (35) | |
| Fair value of vested restricted stock units | - | - | - | - | 103 | - | - | 103 |
| Issuance of common shares for cash and warrants, net of costs | 3,000,000 | 3 | - | - | 9,550 | - | - | 9,553 |
| Cost of stock option modifications and repricing | - | - | - | - | 6 | - | - | 6 |
| Issuance of common stock upon exercise of stock options | 5,000 | - | - | - | 14 | - | - | 14 |
| Net loss during the three months ended March 31, 2025 | - | - | - | - | - | - | (7,492) | (7,492) |
| Balance at March 31, 2025 | 37,733,140 | $38 | (433,333) | $(433) | $289,097 | $29 | $(258,885) | $29,846 |
| Stock compensation | - | - | - | - | 1,290 | - | - | 1,290 |
| Unrealized loss on investments | - | - | - | - | - | (26) | - | (26) |
| Fair value of vested restricted stock units | - | - | - | - | 185 | - | - | 185 |
| Cost of stock option modifications and repricing | - | - | - | - | 7 | - | - | 7 |
| Common stock issued under equity award plans | 25,876 | - | - | - | 52 | - | - | 52 |
| Net loss during the three months ended June 30, 2025 | - | - | - | - | - | - | (7,456) | (7,456) |
| Balance, June 30, 2025 | 37,759,016 | $38 | (433,333) | $(433) | $290,631 | $3 | $(266,341) | $23,898 |
| Stock compensation | 287,762 | - | - | - | 1,623 | - | - | 1,623 |
| Unrealized gain on investments | - | - | - | - | - | 5 | - | 5 |
| Fair value of vested restricted stock units | - | - | - | - | 291 | - | - | 291 |
| Cost of stock option repricing | - | - | - | - | 724 | - | - | 724 |
| Net loss during the three months ended September 30, 2025 | - | - | - | - | - | - | (7,950) | (7,950) |
| Balance, September 30, 2025 | 38,046,778 | $38 | (433,333) | $(433) | $293,269 | $8 | $(274,291) | $18,591 |
| Common Stock · Treasury Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Total | |
| Balance, December 31, 2023 | 26,788,986 | $27 | (433,333) | $(433) | $241,389 | $14 | $(221,524) | $19,473 |
| Stock compensation | - | - | - | - | 1,489 | - | - | 1,489 |
| Unrealized loss on investments | - | - | - | - | - | (19) | - | (19) |
| Fair value of vested restricted stock units | 131,267 | - | - | - | 989 | - | - | 989 |
| Issuance of common shares for cash and warrants, net of costs | 76,487 | - | - | - | 688 | - | - | 688 |
| Cost of stock option modifications and repricing | - | - | - | - | 314 | - | - | 314 |
| Net loss during the three months ended March 31, 2024 | - | - | - | - | - | - | (7,850) | (7,850) |
| Balance, March 31, 2024 | 26,996,740 | $27 | (433,333) | $(433) | $244,869 | $(5) | $(229,374) | $15,084 |
| Stock compensation | - | - | - | - | 1,298 | - | - | 1,298 |
| Unrealized loss on investments | - | - | - | - | - | (6) | - | (6) |
| Fair value of vested restricted stock units | - | - | - | - | 136 | - | - | 136 |
| Cost of stock option modifications and repricing | - | - | - | - | 6 | - | - | 6 |
| Issuance of common shares for cash and warrants, net of costs | 7,500,000 | 8 | - | - | 27,670 | - | - | 27,678 |
| Common stock issued under equity award plans | 15,902 | - | - | - | 49 | - | - | 49 |
| Net loss during the three months ended June 30, 2024 | - | - | - | - | - | - | (6,576) | (6,576) |
| Balance, June 30, 2024 | 34,512,642 | $35 | (433,333) | $(433) | $274,028 | $(11) | $(235,950) | $37,669 |
| Stock compensation | - | - | - | - | 1,521 | - | - | 1,521 |
| Unrealized gain on investments | - | - | - | - | - | 135 | - | 135 |
| Fair value of vested restricted stock units | 25,543 | - | - | - | 227 | - | - | 227 |
| Cost of stock option modifications and repricing | - | - | - | - | 6 | - | - | 6 |
| Net loss during the three months ended September 30, 2024 | - | - | - | - | - | - | (6,467) | (6,467) |
| Balance, September 30, 2024 | 34,538,185 | $35 | (433,333) | $(433) | $275,782 | $124 | $(242,417) | $33,091 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.